Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations

被引:15
|
作者
Tamirat, Mahlet Z. [1 ]
Kurppa, Kari J. [2 ]
Elenius, Klaus [2 ,3 ,4 ,5 ]
Johnson, Mark S. [1 ]
机构
[1] Abo Akad Univ, Struct Bioinformat Lab, Biochem, Fac Sci & Engn, Turku 20520, Finland
[2] Univ Turku, Inst Biomed, MediC Res Labs, Turku 20520, Finland
[3] Turku Univ Hosp, Dept Oncol, Turku 20521, Finland
[4] Univ Turku, Turku Biosci Ctr, Turku 20520, Finland
[5] Abo Akad Univ, Turku 20520, Finland
基金
芬兰科学院;
关键词
EGFR tyrosine kinase; exon 20 insertion mutations; non-small cell lung cancer; molecular dynamics simulation; structural biology; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; KINASE DOMAIN; SOMATIC MUTATIONS; CLINICAL-RESPONSE; ERBB RECEPTORS; ACTIVATION; MECHANISM; INSIGHTS; ADENOCARCINOMAS;
D O I
10.3390/cancers13051120
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Non-small cell lung cancer (NSCLC) is the most common type of lung cancer that claims the lives of many worldwide. Activating mutations occurring on the epidermal growth factor receptor (EGFR) protein have been associated with the pathogenesis of NSCLC, among which exon 20 insertion mutations play a significant role. The objective of this study is to examine the dynamic structural changes occurring on the EGFR protein as a result of two common EGFR exon 20 insertion mutations, V769insASV and D770insNPG. The study further aims to uncover the mechanisms by which the insertion mutations increase kinase activity. Our results suggest that the insertion mutations stabilize structural elements key to maintaining the active EGFR conformation. Furthermore, the insertions disrupt an interaction essential in stabilizing the inactive conformation, which could drive the kinase from an inactive to an active EGFR state. Activating somatic mutations of the epidermal growth factor receptor (EGFR) are frequently implicated in non-small cell lung cancer (NSCLC). While L858R and exon 19 deletion mutations are most prevalent, exon 20 insertions are often observed in NSCLC. Here, we investigated the structural implications of two common EGFR exon 20 insertions in NSCLC, V769insASV and D770insNPG. The active and inactive conformations of wild-type, D770insNPG and V769insASV EGFRs were probed with molecular dynamics simulations to identify local and global alterations that the mutations exert on the EGFR kinase domain, highlighting mechanisms for increased enzymatic activity. In the active conformation, the mutations increase interactions that stabilize the alpha C helix that is essential for EGFR activity. Moreover, the key Lys745-Glu762 salt bridge was more conserved in the insertion mutations. The mutants also preserved the state of the structurally critical aspartate-phenylalanine-glycine (DFG)-motif and regulatory spine (R-spine), which were altered in wild-type EGFR. The insertions altered the structure near the ATP-binding pocket, e.g., the P-loop, which may be a factor for the clinically observed tyrosine kinase inhibitor (TKI) insensitivity by the insertion mutants. The inactive state simulations also showed that the insertions disrupt the Ala767-Arg776 interaction that is key for maintaining the "alpha C-out" inactive conformation, which could consequently fuel the transition from the inactive towards the active EGFR state.
引用
收藏
页码:1 / 21
页数:21
相关论文
共 50 条
  • [41] EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
    Jorge, Susan E.
    Lucena-Araujo, Antonio R.
    Yasuda, Hiroyuki
    Piotrowska, Zofia
    Oxnard, Geoffrey R.
    Rangachari, Deepa
    Huberman, Mark S.
    Sequist, Lecia V.
    Kobayashi, Susumu S.
    Costa, Daniel B.
    CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6548 - 6555
  • [42] Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity
    Zhao, Hanchen
    Beyett, Tyler S.
    Jiang, Jie
    Rana, Jaimin K.
    Schaeffner, Ilse K.
    Santana, Jhasmer
    Janne, Pasi A.
    Eck, Michael J.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2024, 121 (45)
  • [43] Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC
    van Veggel, Bianca
    de Langen, Adrianus J.
    Hashemi, Sayed M. S.
    Monkhorst, Kim
    Heideman, Danielle A. M.
    Thunnissen, Erik
    Smit, Egbert F.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1222 - 1226
  • [44] Subtype of EGFR exon 19 deletion mutations
    Fujimoto, Nobukazu
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (01) : 195 - 198
  • [45] Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
    Pacini, Laura
    Jenks, Andrew D.
    Vyse, Simon
    Wilding, Christopher P.
    Arthur, Amani
    Huang, Paul H.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2021, 14 : 301 - 317
  • [46] Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
    Beau-Faller, M.
    Prim, N.
    Ruppert, A. -M.
    Nanni-Metellus, I.
    Lacave, R.
    Lacroix, L.
    Escande, F.
    Lizard, S.
    Pretet, J. -L
    Rouquette, I.
    de Cremoux, P.
    Solassol, J.
    de Fraipont, F.
    Bieche, I.
    Cayre, A.
    Favre-Guillevin, E.
    Tomasini, P.
    Wislez, M.
    Besse, B.
    Legrain, M.
    Voegeli, A. -C.
    Baudrin, L.
    Morin, F.
    Zalcman, G.
    Quoix, E.
    Blons, H.
    Cadranel, J.
    ANNALS OF ONCOLOGY, 2014, 25 (01) : 126 - 131
  • [47] Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer
    Huang, Wei-Sheng
    Li, Feng
    Gong, Yongjin
    Zhang, Yun
    Youngsaye, Willmen
    Xu, Yongjin
    Zhu, Xiaotian
    Greenfield, Matthew T.
    Kohlmann, Anna
    Taslimi, Paul M.
    Toms, Angela
    Zech, Stephan G.
    Zhou, Tianjun
    Das, Biplab
    Jang, Hyun G.
    Tugnait, Meera
    Ye, Yihua E.
    Gonzalvez, Francois
    Baker, Theresa E.
    Nadworny, Sara
    Ning, Yaoyu
    Wardwell, Scott D.
    Zhang, Sen
    Gould, Alexandra E.
    Hu, Yongbo
    Lane, Weston
    Skene, Robert J.
    Zou, Hua
    Clackson, Tim
    Narasimhan, Narayana I.
    Rivera, Victor M.
    Dalgarno, David C.
    Shakespeare, William C.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 80
  • [48] Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations
    Hu, Meng
    Zhong, Congying
    Wang, Jiabing
    Chen, JinQin
    Zhou, Tao
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [49] Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations
    Vliegen, Liesbet
    Dooms, Christophe
    De Kelver, Wim
    Verbeken, Eric
    Vansteenkiste, Johan
    Vandenberghe, Peter
    DIAGNOSTIC PATHOLOGY, 2015, 10
  • [50] Clinicopathological Characteristics of 11 NSCLC Patients with EGFR-Exon 20 Mutations
    Lund-Iversen, Marius
    Kleinberg, Lilach
    Fjellbirkeland, Lars
    Helland, Aslaug
    Brustugun, Odd Terje
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : 1471 - 1473